Psych MEQs / SAQs · Child and adolescent psychiatry — OCRD
Childhood-onset OCD — ERP, POTS and SSRI monitoring (MEQ)
FRANZCP-style modified essay on paediatric OCD diagnosis, CY-BOCS, family accommodation, ERP, SSRI monitoring, and POTS evidence.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Diagnosis and differentials. Working diagnosis: obsessive-compulsive disorder, childhood-onset, multi-dimensional (contamination/washing, symmetry/rewriting, checking) with marked time cost and impairment, good-to-fair insight suggested by shame/ego-dystonic tone of harm thoughts. Not primarily psychotic. Differentials: ASD routines (less fitting ego-dystonic anxiety here), complex tics (screen for tic-related specifier), GAD, illness anxiety, depression, body-focused OCRDs if relevant. PANDAS/PANS less likely with gradual multi-year course and no acute post-infectious story — mention concept without forcing work-up as default.[3][7]
(ii) Assessment. Multi-informant history of content, hours, avoidance, school impact, risk (self-harm, harm-obsessions distress, neglect of self-care). Inventory family accommodation (reassurance, participation, restricted outings).[6] Screen tics, ADHD, mood, ASD traits, substances, safeguarding/bullying. Use CY-BOCS for severity baseline and tracking.[4] Shared formulation with youth and carers.
(iii) Stepped management. Psychoeducation: OCD loop, not wilful; reduce accommodation as treatment target. First-line psychological: CBT with ERP — hierarchy, exposure without rituals (including mental reviewing and reassurance), homework, carer coaching; evidence supports CBT effect sizes in paediatric meta-analysis.[9][3] For this moderate–severe multi-hour presentation, discuss SSRI concurrent or sequential: e.g. sertraline start approximately 25 mg oral daily, titrate toward paediatric OCD ranges often up to about 50–200 mg/day; alternatives fluoxetine (e.g. 10 then 20 mg, titrate toward ~20–60 mg) with black-box suicidality/activation monitoring, early review, carer education. Adequate trial ~8–12 weeks at therapeutic dose. Verify local PI.[5][8][3]
(iv) POTS / POTS II. POTS: CBT and sertraline each beat placebo; combination particularly effective for severe illness — justifies combined pathway here.[1] POTS II: if partial SRI response, add/intensify CBT rather than medication management alone.[2] (Note POTS Jr if examiner asks about under-8s — family-based CBT.)[10]
(v) School and risk. Risk assess forbidden-harm thoughts (ego-dystonic vs intent), suicide/self-harm, skin breakdown, school refusal. School plan: gradual return, bathroom timing accommodations without enabling endless washing, anti-bullying, staff psychoeducation. Written crisis contacts; follow-up for ERP and medication titration.[3]
Common errors
- Treating harm obsessions as imminent risk of violence without distinguishing ego-dystonic OCD.
- Generic supportive therapy without naming ERP.
- Ignoring family accommodation.
- Declaring SSRI failure after days, or omitting black-box monitoring.
- Routine PANDAS antibiotics for gradual OCD. [1][3][6][7]
Examiner notes
Full marks require DSM logic, CY-BOCS, accommodation, ERP structure, SSRI example with monitoring, and named POTS/POTS II implications. [1][2][4]
References
- [1]Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial JAMA, 2004.PMID 15507582
- [2]Franklin ME, Sapyta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial JAMA, 2011.PMID 21934055
- [3]American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder J Am Acad Child Adolesc Psychiatry, 2012.PMID 22176943
- [4]Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity J Am Acad Child Adolesc Psychiatry, 1997.PMID 9183141
- [5]March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial JAMA, 1998.PMID 9842950
- [6]Calvocoressi L, Lewis B, Harris M, et al. Family accommodation in obsessive-compulsive disorder Am J Psychiatry, 1995.PMID 7864273
- [7]Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases Am J Psychiatry, 1998.PMID 9464208
- [8]Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial J Am Acad Child Adolesc Psychiatry, 2001.PMID 11437015
- [9]Watson HJ, Rees CS Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder J Child Psychol Psychiatry, 2008.PMID 18400058
- [10]Freeman J, Sapyta J, Garcia A, et al. Family-based treatment of early childhood obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr)—a randomized clinical trial JAMA Psychiatry, 2014.PMID 24759852